A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine
Public ClinicalTrials.gov record NCT02915744. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is an open-label, randomized, active comparator, multicenter, international Phase 3 study of NKTR-102 versus TPC in patients with metastatic breast cancer who have stable brain metastases and have been previously treated with an anthracycline, a taxane, and capecitabine in either the adjuvant or metastatic setting (prior anthracycline may be omitted if medically appropriate or contraindicated for the patient).
Study identification
- NCT ID
- NCT02915744
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 178 participants
Conditions and interventions
Conditions
Interventions
- NKTR-102 Drug
- Eribulin Drug
- Ixabepilone Drug
- Vinorelbine Drug
- Gemcitabine Drug
- Paclitaxel Drug
- Docetaxel Drug
- Nab-paclitaxel Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 2016 (Type not available)
- Primary completion
- Jul 2020 (Actual)
- Completion
- Jul 2020 (Actual)
- Last update posted
- Apr 14, 2023
2016 – 2020
United States locations
- U.S. sites
- 19
- U.S. states
- 15
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Investigator Site - Tucson | Tucson | Arizona | 85724 | — |
| Investigator Site - Orange | Orange | California | 92868 | — |
| Investigator Site - San Francisco | San Francisco | California | 94115 | — |
| Investigator Site - Miami | Miami | Florida | 33136 | — |
| Investigator Site - Plantation | Plantation | Florida | 33324 | — |
| Investigator Site - West Palm Beach | West Palm Beach | Florida | 33401 | — |
| Investigator Site - Athens | Athens | Georgia | 30607 | — |
| Investigator Site - Baltimore | Baltimore | Maryland | 21201 | — |
| Investigator Site - Boston | Boston | Massachusetts | 02115 | — |
| Investigator Site - Minneapolis | Minneapolis | Minnesota | 55455 | — |
| Investigator Site - Saint Louis | St Louis | Missouri | 63110 | — |
| Investigator Site - New York | New York | New York | 10065 | — |
| Investigator Site - Chapel Hill | Chapel Hill | North Carolina | 27599 | — |
| Investigator Site - Columbus | Columbus | Ohio | 43210 | — |
| Investigator Site - Germantown | Germantown | Tennessee | 38138 | — |
| Investigator Site - Fort Worth | Fort Worth | Texas | 76104 | — |
| Investigator Site - Houston | Houston | Texas | 77030 | — |
| Investigator Site - Salt Lake City | Salt Lake City | Utah | 84106 | — |
| Investigator Site - Seattle | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 37 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02915744, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 14, 2023 · Synced Nov 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02915744 live on ClinicalTrials.gov.